Sponsor
Neuromed IRCCS
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Neuromed IRCCS appears in 43 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
43 shownPrecision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.NCT07467460 · lead sponsor · 2026-02-17
RECRUITINGDiscovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative DisordersNCT06803784 · lead sponsor · 2025-02-04
RECRUITINGEffects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple SclerosisNCT05811013 · lead sponsor · 2023-05-27
RECRUITINGBiomarkers of Synaptic Damage in Multiple SclerosisNCT03217396 · lead sponsor · 2017-11-22
RECRUITINGItalian Validation of the dNA Scale and Its Correlation With Neurocognitive VariablesNCT07533084 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGTargeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MSNCT05779449 · lead sponsor · 2023-07-26
UNKNOWNThe Southern Italian Children, Adolescents and PaRents COhort Study on Nutrition and HealthNCT05784376 · lead sponsor · 2023-07-01
UNKNOWNParkinson's Disease and Gamma-transcranial Alternating Current StimulationNCT06297538 · lead sponsor · 2023-04-29
UNKNOWNNon-invasive Assessment of Synaptic PlasticityNCT05353517 · lead sponsor · 2022-12-01
UNKNOWNHandwriting Analysis in Movement DisordersNCT05355480 · lead sponsor · 2022-12-01
UNKNOWNPsychometric Evaluation in Patients With Brain Damage During NeuroinflammationNCT05450237 · lead sponsor · 2022-07-01
ENROLLING_BY_INVITATIONCompassion Program for ParkinsonNCT05410769 · lead sponsor · 2022-07-01
UNKNOWNInstrumental Assessment of Motor Symptoms by Means of Wearable Sensors in Patients With Parkinson's DiseaseNCT05349539 · lead sponsor · 2022-06-01
UNKNOWNEfficacy of Oral Administration of Trehalose in Patients With Parkinson DiseaseNCT05355064 · lead sponsor · 2022-05-01
UNKNOWNEffects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical StudyNCT05245344 · lead sponsor · 2022-04-01
UNKNOWNNew Biomarkers in Parkinson's DiseaseNCT05150158 · lead sponsor · 2021-12-01
UNKNOWNAssessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's DiseaseNCT04620980 · lead sponsor · 2021-06-15
UNKNOWNCoagulation Activation by Hyperosmolar Agents in Intracranial HypertensionNCT03409237 · lead sponsor · 2020-12-03
WITHDRAWNRole of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)NCT04121065 · lead sponsor · 2020-09-07
UNKNOWNMetabotropic Receptors For Glutamate Type 3 In Parkinson'sNCT03998787 · lead sponsor · 2020-03-01
UNKNOWNmiR-142-3p as Potential Biomarker of Synaptopathy in MSNCT03999788 · lead sponsor · 2019-12-10
UNKNOWNNovel Approaches of Advanced Neuroimaging Based on MRI Fiber Tracking to Detect Early Signs of Vascular Cognitive Impairment in Hypertensive PatientsNCT03986957 · lead sponsor · 2019-12-09
UNKNOWNExercise-based Therapy for Multiple Sclerosis PatientsNCT03735524 · lead sponsor · 2019-05-01
UNKNOWNLipid Mediators in Multiple SclerosisNCT03492606 · lead sponsor · 2019-03-01
COMPLETEDCcf mtDNA as a Neurodegenerative BiomarkerNCT03938909 · lead sponsor · 2019-03-01
UNKNOWNmiRNAs Profiling in Parkinson's DiseaseNCT03466723 · lead sponsor · 2019-02-14
COMPLETEDDiabetes Risk Diagnosis and ManagementNCT03949504 · lead sponsor · 2019-01-09
COMPLETEDStudy on the Visual Condition in Parkinson's DiseaseNCT03743467 · lead sponsor · 2018-11-05
UNKNOWNEvaluation of Splenic Metabolic Activity With 18FDG-PET in HypertensionNCT02572765 · lead sponsor · 2018-01-02
UNKNOWNEconomic Crisis and Adherence to the Mediterranean Diet (CASSIOPEA)NCT03119142 · lead sponsor · 2017-05-02
COMPLETEDPrismatic Lenses in the Pisa SyndromeNCT03737773 · lead sponsor · 2016-07-01
COMPLETEDEffects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive PatientsNCT02572219 · lead sponsor · 2015-11-01
COMPLETEDDiagnostic Tools for Parkinson's DiseaseNCT02403765 · lead sponsor · 2015-05-01
COMPLETEDValidation of New Tools for the Assessment of Cognitive Functions and Connectivity Network in Hypertensive PatientsNCT02310217 · lead sponsor · 2015-02-01
COMPLETEDEvaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive SubjectsNCT02312193 · lead sponsor · 2015-01-01
COMPLETEDSupplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast CancerNCT02195960 · lead sponsor · 2014-06-09
COMPLETEDImmunological Profile in Relation to Cardiac Geometry in HypertensionNCT02165241 · lead sponsor · 2014-06-01
UNKNOWNWorking on Asymmetry in Parkinson's DiseaseNCT02051556 · lead sponsor · 2014-03-01
UNKNOWNThe Moli-sani StudyNCT03242109 · lead sponsor · 2005-03-01
COMPLETEDItalian Digital Primary Cardiovascular Prevention StudyNCT05339841 · collaborator · 2022-06-10
ACTIVE_NOT_RECRUITINGExercise Therapy in Multiple SclerosisNCT04294979 · collaborator · 2020-02-01
COMPLETEDEvaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)NCT02843529 · collaborator · 2016-10-17
COMPLETEDStudy on the Relationship Between Environmental and Occupational Exposure to Metals and Parkinson's DiseaseNCT02588924 · collaborator · 2015-09-01
UNKNOWNDrugs studied in this sponsor's trials
2 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Neuromed IRCCS as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
mannitol1
trehalose1
Sponsor roles
lead sponsor39
collaborator4
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.